NCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting
Clinical Trials
8 trialsNCT04711109 2025-04-02
BRCA-P
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT03401060 2024-05-03
DenosuMast
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT06314698 2024-03-18
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
RenJi Hospital
Phase 3 Not yet recruiting
NCT03324932 2023-10-06
Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer
Kyoto Prefectural University of Medicine
Phase 3 Active not recruiting
NCT03408652 2021-10-22
MOSCAR
Centre Leon Berard
Phase 3 Terminated
NCT03027557 2021-05-25
DENOCINA
Aalborg University Hospital
Phase 3 Completed
NCT03259152 2017-08-24
D-Gct
Hebei Medical University Third Hospital
Phase 3 Unknown